Artera has updated its ArteraAI Prostate Test. The update of the test report gives insight into a patient's relative risk of cancer, showing more aggressive features, which can guide whether active surveillance is appropriate. Details on pricing were not disclosed.

The company asserts that the updated test will enhance reliability and robustness, aiding strategies for cancer therapy. It will also enhance the information available to clinicians, providing additional insights for decisions around active surveillance.

The test, which supports clinicians in making decisions about active surveillance for prostate cancer patients, leverages Artera's multimodal artificial intelligence platform. The ArteraAI Prostate Test is methodically designed to anticipate the patient's cancer progression and predict the therapeutic benefits in localized prostate cancer.

Analyst QuickTake: In March 2024 , the company announced that The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Prostate Cancer had included the ArteraAI test, marking it as the first AI-enabled predictive and prognostic test recommended for localized prostate cancer.